Press Releases

  • 12 April 2017
    Partnership Agreement finalized with PENTAX Europe GmbH regarding sales and marketing of absorbable local hemostat“PuraStat®”in France, the Netherlands, and Portugal
  • 04 April 2017
    Execution of License Agreement for Hemostat in China
  • 28 April 2016
    Partnership Agreement concluded with Kaplan regarding sales and marketing of absorbable local hemostat "PuraStat®"in Chile
  • 05 April 2016
    [Delayed] Patent Granted for "Cardiac Tissue Regeneration" with Self-Assembling Peptide Technology in Japan
  • 22 February 2016
    Absorbable Hemostat PuraStat® Product Registration Obtained in Mexico
  • 18 February 2016
    Partnership Agreement concluded with Genelife S.A regarding sales and marketing of absorbable local hemostat "PuraStat®" in Mexico
  • 15 February 2016
    Announcement of Change of Representative Directors
  • 10 February 2016
    Revision of Forecast of Financial Results for FY2015 and Extraordinary loss
  • 25 January 2016
    Absorbable Hemostat PuraStat® Product Registration Obtained in Thailand
  • 22 January 2016
    Absorbable Hemostat PuraStat® Product Registration Obtained in Australia
  • 05 January 2016
    Patent granted on "3-D Cell Culture Scaffold" in Canada with self-assembling peptide technology exclusively licensed by MIT
  • 28 December 2015
    Partnership Agreement concluded with Transmedic Pte Ltd regarding sales and marketing of 「PuraStat®」in Singapore, Malaysia and Brunei
  • 04 November 2015
    Absorbable Hemostat "TDM-621" Product Registration Obtained in Brazil
  • 05 October 2015
    Partnership Agreement concluded with Maquet Australia Pty Ltd regarding sales and marketing of absorbable local hemostat 「PuraStat®」in Australia
  • 15 September 2015
    Patent Granted for "Transfection Agent (Agent for Transfer of Nucleic Acids into Cells)" Using the 3D-Matrix Peptide Technology
  • 23 July 2015
    Absorbable Hemostat "TDM-621" Product Registration Obtained in Colombia
  • 10 July 2015
    Partnership Agreement concluded with Daewoong Pharmaceutical Co., Ltd. regarding sales and marketing of absorbable local hemostat 「PuraStat®」in ASEAN
  • 7 July 2015
    Start of an Investigator-Initiated Clinical Trial for Treatment-Resistant Breast Cancer Patients with Novel siRNA Nucleic Acid Formulation “TDM-812” at the National Cancer Center
  • 27 May 2015
    Subsidiary Foundation in the Netherlands

Consolidated Financial Report

  • 15 Mar 2016
    CONSOLIDATED FINANCIAL REPORT For the Third Quarter of Fiscal Year Ending April 30, 2016 (Under Japan GAAP)
  • 15 December 2015
    CONSOLIDATED FINANCIAL REPORT For the Second Quarter of Fiscal Year Ending April 30, 2016
  • 7 September 2015
    For the First Quarter of Fiscal Year Ending April 30, 2016 (Under Japan GAAP)
  • 12 June 2015
    Consolidated Financial Report For the Fiscal Year Ended April 30, 2015 (Under Japan GAAP)

Most Recent Financial Statements

  •  

Mid-Term Business Plan

  • 12 June 2015
    FY2015-FY2017 Mid-Term Business Plan

Other

  • 26 January 2016
    Business Analysis Report by Shared Research Inc.
  • 2 October 2015
    Business Analysis Report by Shared Research Inc.
  • 7 September 2015
    Business Analysis Report by Shared Research Inc.
  • 12 June 2015
    Business Analysis Report by Shared Research Inc.
IR Library  
Stock Information  
Stock Price Information  
IR Inquiries  
Disclaimer